Zanganeh Mahkam 4

What Happened
Director Zanganeh Mahkam received two equity awards from Pulse Biosciences on June 11, 2026, consisting of 30,000 and 14,504 derivative shares (total 44,504). Both awards are reported as derivative grants with a reported price of $0.00 — i.e., no cash paid by the reporting person. These are grants (compensation) rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-06-11; Filing date: 2026-06-15 (timely under Form 4 rules).
• Transaction codes: A (award/grant/other acquisition) — derivative securities reported.
• Amounts: 30,000 shares and 14,504 shares; price reported $0.00 for each grant.
• Vesting: The 30,000-share award vests in equal monthly installments over one year, first vesting on July 11, 2026 (Footnote F1). The 14,504-share award vests in equal quarterly installments over one year, first vesting on September 5, 2026 (Footnote F2).
• Shares owned after transaction: not disclosed in the provided filing.
• No sale or cashless exercise reported — these are awards that will vest over time.

Context
These are standard director compensation awards: they do not require cash outlay by the insider and will vest over the stated schedules before becoming owned shares. Because they are grants (not purchases or sales), they reflect compensation rather than an immediate bullish or bearish trading signal.